Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer
PubMed Full text in PMC Similar studies Analyze with GEO2R
Microarray gene expression data from MCF-7 and LetR cells
Synergistic targeting of estrogen-receptor positive breast cancers by MDM2 inhibition in combination with endocrine therapy or CDK4/6 inhibition
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome
PubMed Full text in PMC Similar studies
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome [Affymetrix]
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome [Illumina]
AKT antagonist AZD5363 influences estrogen receptor function in endocrine resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo
PubMed Similar studies Analyze with GEO2R
Gene expression analysis of previously treated hormone receptor-positive metastatic breast cancer
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies
PubMed Similar studies Analyze with GEO2RSRA Run Selector
Gene expression analyses of palbociclib treated ER+ breast cancer cell lines as assessed by RNA-seq
Gene expression profiling of breast cancer cells with knockdown of PTEN
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer
transCONFIRM gene expression analysis
SMAD2 binding regions in breast cancer cell line and RNA-seq transcriptome analyses in T47D
RNA-seq transcriptome analyses in T47D cells treated with ActA and Palbociclib.
SMAD2 binding regions in triple negative breast cancer cell line, Hs578T
PubMed Full text in PMC Similar studies SRA Run Selector
SMAD2 binding regions in estrogen receptor-positive breast cancer cell line, T47D
Breast Cell Lines: Experimental vs. Mixed Reference
Genome-wide copy number profiling of MCF-7 and fulvestrant-resistant MCF-7/FR cells by SNP microarray.
Fulvestrant withdrawal from fulvestrant-resistant MCF-7/FR cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on